- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher health care system expenses. Economic mitigation strategies include implementing early screening programs, improving diagnostic technologies, enhancing medical training, and developing robust health care infrastructure that prioritizes timely patient assessment and intervention.
EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa
EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models
EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management
EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence
EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
EP: 12.Navigating HS Management: The Patient Journey
EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement
EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes
Video content above is prompted by the following:
- What are the economic implications of delayed diagnosis on both patients and health systems, and how can these be mitigated?
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL
April 3rd 2025In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Read More
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
